MAM
MNPR icon

Meeder Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Meeder Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9K Sell
637
-357
-36% -$21.6K ﹤0.01% 493
2025
Q4 		$64.9K Buy
+994
New +$81.2K ﹤0.01% 372

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Meeder Asset Management's MNPR Position: Q1 2026 in Review

Meeder Asset Management reduced its Monopar Therapeutics (MNPR) stake by 36% in Q1 2026, selling an estimated $21.6K and leaving 637 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #493.

Meeder Asset Management first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $64.9K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Meeder Asset Management held 637 shares of Monopar Therapeutics worth $34.9K as of Q1 2026.
  • Meeder Asset Management sold 357 Monopar Therapeutics shares in Q1 2026, an estimated $21.6K.
  • Monopar Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #493 holding.
  • Meeder Asset Management first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Meeder Asset Management's Monopar Therapeutics position peaked at $64.9K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.